Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2018 - 2026)

Protalix BioTherapeutics' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 17.65% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 17.65% YoY), while the FY2025 annual figure was $2.5 million, down 11.9% from the prior year.
• Long-Term Deferred Tax was $2.4 million for Q1 2026 at Protalix BioTherapeutics, down from $2.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $3.3 million in Q2 2024 to a low of $2.4 million in Q1 2026.
• Historically, Long-Term Deferred Tax has averaged $2.9 million across 4 years, with a median of $2.9 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Long-Term Deferred Tax advanced 5.4% in 2024, then declined 17.65% in 2026.
• A 4-year view of Long-Term Deferred Tax shows it stood at $3.1 million in 2023, then dropped by 7.63% to $2.9 million in 2024, then retreated by 11.9% to $2.5 million in 2025, then retreated by 2.82% to $2.4 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $2.4 million (Q1 2026), $2.5 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.